150 hospitals. 14 countries. One pathogen: Staphylococcus aureus bloodstream infections. The SNAP Trial is the largest international clinical trial ever conducted for golden staph [5]. That scale is not a boast. It is an admission that no one knows what works anymore.
One in six laboratory-confirmed bacterial infections were resistant to antibiotic treatments in 2023, according to the WHO's Global Antibiotic Resistance Surveillance report [2]. More than 40% of antibiotics lost potency against common blood, gut, urinary tract and sexually-transmitted infections between 2018 and 2023 [2]. Golden staph sits in the middle of this collapse.
The WHO report gathered data on more than 23 million bacterial infections from 104 countries [2]. That is the numerator. The denominator, total bacterial infections, laboratory-confirmed or not, remains unknown. Every resistance percentage in circulation is built on a fraction of unknown size.
One in three bacterial infections in south-east Asia and the eastern Mediterranean were resistant to antibiotics in 2023 [2]. In the WHO African region, resistance to third-generation cephalosporins often exceeds 70% [2]. The trial needed 14 countries because resistance patterns are not uniform. What works in one region fails in another.
In 2021, 7.7 million people globally died from bacterial infections [2]. Drug resistance contributed to 4.71 million of those deaths, with 1.14 million deaths directly attributed to resistance [2]. Golden staph is a fraction of that 1.14 million. The exact fraction is not reported.
The number of antimicrobial resistance deaths is expected to increase 70% by 2050 [2]. That projection justified a 150-hospital trial for a single pathogen.
The SNAP Trial was led by researchers at the Peter Doherty Institute for Infection and Immunity and the University of Newcastle [5]. The trial will report which antibiotics work best for golden staph bloodstream infections. A question that used to be settled by a single-center study now requires 150 hospitals across 14 countries [5].
That expansion is not a sign of ambition. It is a measure of how far certainty has receded, and how much infrastructure is now required to recover a single reliable answer in an environment where resistance has fractured treatment into regional guesswork.
